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Miliary pulmonary tuberculosis after the first dose 
of intravesical BCG instillation in a patient 
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A 62 years old patient, who was diagnosed with high-grade T1 (T1HG) bladder cancer, after transurethral 
resection (TURB) (February 2018) and re-TURB (March 2018), with a history of diabetes mellitus type 2, hy-
pertension, dyslipidemia, coronary artery disease and three percutaneous coronary interventions was admitted 
to the Urology Department. On admission he presented features of acute liver failure and right ventricular 
heart failure, accompanied by high fever, general malaise and elevated inflammatory response markers, which 
occurred after the first intravesical Bacillus Calmette-Guérin (BCG) instillation. The immunotherapy was 
started two weeks before hospitalization. Computed tomography (CT) revealed hepato- and splenomegaly, 
a small amount of fluid in the peritoneal cavity and slightly thickened wall of the bladder (7 mm). 
The patient was relocated to the Pulmonology Department in serious general condition, presenting 
features of respiratory failure, decompensated heart failure and hectic fever up to 39ºC. On physical exam-
ination bibasal crackles, hepatomegaly and peripheral oedema were found. Moreover, elevated values of 
C-reactive protein (109.2 mg/L), procalcitonine (0.87 ng/mL), alanine aminotransferase (104 U/L), aspartate 
aminotransferase (124 U/L), alkaline phosphatase (823 U/L) and gamma-glutamyl transpeptidase (1130 U/L) 
were detected. A bronchoalveolar lavage (BAL) was performed twice to take samples for cytologic, bacterio-
logical and mycological tests as well as Bactec and ProbeTecET genetic probes. Moreover, bronchofiberoscopy 
with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) of subcarinal lymph 
nodes did not point towards a proliferative disease. In addition, blood and urine culture, diagnostic tests for 
infectious diseases particularly for HIV, were carried out. The BAL findings were positive for Mycobacterium 
tuberculosis complex in genetic testing. Other microbiological tests were negative. A chest CT scan pointed 
to multiple lung changes which composed a picture of miliary pulmonary tuberculosis with concomitant 
oedematous lesions (Figure 1A). 
The patient was treated with passive oxygen therapy, broad-spectrum antibiotics (meropenem, levofloxa-
cin and vancomycin), itraconazole and systemic corticosteroids. The first intensive phase of anti-tuberculosis 
treatment targeting Mycobacterium bovis was started with isoniazid (INH), rifampicin (RMP) and ethambutol 
(EMB). As a result, a significant improvement of general condition was observed with resolution of fever and 
normalization of laboratory results. The corticosteroid treatment has been continued in decreasing doses for 
3 months, whereas anti-tuberculosis regimens for 6 months (INH, RMP, EMB treatment for 2 months followed 
by continuation phase of INH and RMP for 4 months). In a control chest CT near complete remission of pul-
monary changes was stated (Figure 1B).
Currently, BCG immunotherapy is considered as the gold standard treatment for non-muscle invasive 
bladder cancer at high risk of progression or recurrence [1]. Progression-free survival at three years observation 
is 86.8% and results are better in comparison to local chemotherapy [2, 3]. Nevertheless, the BCG immunother-
apy could be associated with the wide spectrum of adverse effects like dysuria, pyrexia, hematuria or fatigue 
in 69.5–91% of cases [4]. The pulmonary involvement is observed only in 0.3–0.7% of treated patients [4]. 
Our literature search yielded 35 similar case reports published so far. Moreover, among them only 1 occurred 
after the first dose of BCG instillation as in our report [5].
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Figure 1A. The chest computed tomography (CT) is indicative of lung micronodular lesions (0.5–1 mm) accompanied by oedematous changes. 
Small pleural effusion in the both pleural cavities can be seen. Bilaterally, particularly in the dorsal segments of the lungs, alveolar consolidation 
and signs of septal thickening are present. B. In comparison to the previous chest CT, after 2 months of treatment, there has been complete 
resolution of fluid in the pleural cavities. Also noticeable is a nearly complete resolution of lung micronodules with only few up to 0.5 mm in 
diameter still present
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